MDCO reports positive Phase II trial results of PCSK9si to treat hypercholesterolemia

The Medicines Company (MDCO) has reported positive topline results from its Phase II trial of single or multiple subcutaneous injections of PCSK9 synthesis inhibitor (PCSK9si).

Source: Drug Development Technology - October 19, 2016 Category: Pharmaceuticals Source Type: news